Outcome of Board Meeting today and Financial Results
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported strong FY26 results with standalone PAT growing 63.6% to ₹521 million from ₹318.42 million in FY25, while consolidated PAT nearly doubled to ₹574.84 million from ₹288.26 million. Standalone revenue grew marginally by 2% to ₹2,921.36 million, and consolidated revenue rose 6.9% to ₹3,325.99 million. The Board recommended a dividend of ₹11 per share (110%) for FY26. Statutory auditors issued unmodified opinions on both standalone and consolidated financials. The company divested 43.81% stake in subsidiary Texas Lifescience Private Limited in March 2026, generating an exceptional gain of ₹69.96 million on standalone basis. Ms. Priya Gandhi (daughter of CEO Rajiv Gandhi) was reappointed as Executive Director for 3 years from October 2026.
The robust PAT growth of 63-99% significantly exceeds expectations and signals strong operational performance, which could be positive for the stock. The modest revenue growth despite strong profit growth suggests improved operational efficiency. The dividend declaration reinforces shareholder-friendly policies.